NanoSmart Welcomes Dr. Vincent F. Simmon to Advisory Board

LAGUNA HILLS, Calif., March 11, 2014 /PRNewswire/ -- NanoSmart Pharmaceuticals, a privately-held pharmaceutical company developing tumor-targeting nanoparticles to treat a variety of solid tumors, has appointed Vincent F. Simmon, Ph.D. to its Advisory Board. Dr. Simmon is a 30-year veteran in business development, corporate leadership, and pharmaceutical product development.

"Vince has a proven track record growing young companies and developing drugs for multiple markets," explains Dr. James Smith, President of NanoSmart Pharmaceuticals, Inc. "His support will be invaluable to NanoSmart as we continue to progress through critical stages of development."

Dr. Simmon has served as Chief Executive Officer or Chief Operating Officer of public and private pharmaceutical companies developing small molecule therapeutics or biologics for the treatment of brain trauma (Xytis, Inc.), cancer (Merrimac Pharmaceuticals, Inc.), and CNS disorders (Cortex Pharmaceuticals, Inc.). As CEO, Dr. Simmon obtained federal, private, and corporate funding for pre-clinical and clinical research studies and oversaw the commercialization of several lead candidates.

"I am pleased to be joining NanoSmart's advisory board," Dr. Simmon stated. "Their technology for enhancing the ability of chemotherapeutics encased in liposomes to target solid tumors is very exciting, and can serve as a platform for multiple products and multiple licensing opportunities."

Dr. Simmon received his doctorate in molecular and microbiology from Brown University and completed his postdoctoral work at Stanford University. He provides business and M&A consulting services to biotechnology companies and sits on the board of directors of Genescient, Inc., Thuris, Inc., and Innovative Neurotechnologies, Inc.

About NanoSmart Pharmaceuticals

NanoSmart Pharmaceuticals, Inc. is a privately-held company engaged in developing novel methods to treat cancer and other diseases. The company is focused on using its patented tumor targeting antibodies to develop a variety of biopharmaceuticals to treat many different types of cancer. This press release may contain forward-looking statements that involve risks and uncertainties associated with financial projections, milestone timelines, clinical development, regulatory approvals and other risks described by NanoSmart from time to time in its periodic reports. None of NanoSmart's drug compounds are approved by the US FDA or by any comparable regulatory agencies elsewhere in the world. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate, and these statements should not be regarded as a representation by NanoSmart or any other person that the objectives and plans of NanoSmart will be achieved.

Contact:
Dan Thiel
VP of Business Development
+1-949-305-2020

SOURCE NanoSmart Pharmaceuticals, Inc.